CIB1

Summary

CIB1 (calcium and integrin binding 1, HGNC:16920) is a protein-coding gene on chromosome 15q26.1, encoding Calcium and integrin-binding protein 1 (Q99828). Calcium-binding protein that plays a role in the regulation of numerous cellular processes, such as cell differentiation, cell division, cell proliferation, cell migration, thrombosis, angiogenesis, cardiac hypertrophy and apoptosis.

This gene encodes a member of the EF-hand domain-containing calcium-binding superfamily. The encoded protein interacts with many other proteins, including the platelet integrin alpha-IIb-beta-3, DNA-dependent protein kinase, presenilin-2, focal adhesion kinase, p21 activated kinase, and protein kinase D. The encoded protein may be involved in cell survival and proliferation, and is associated with several disease states including cancer and Alzheimer’s disease. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 10519 — RefSeq curated summary.

At a glance

• Gene–disease (curated): epidermodysplasia verruciformis, susceptibility to, 3 (Definitive, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 289 total — 10 pathogenic, 5 likely-pathogenic
• Phenotypes (HPO): 18
• Druggable target: yes
• MANE Select transcript: NM_006384

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16920
Approved symbol	CIB1
Name	calcium and integrin binding 1
Location	15q26.1
Locus type	gene with protein product
Status	Approved
Aliases	SIP2-28, CIB, KIP
Ensembl gene	ENSG00000185043
Ensembl biotype	protein_coding
OMIM	602293
Entrez	10519

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 6 retained_intron, 5 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000328649, ENST00000612800, ENST00000650306, ENST00000695870, ENST00000695871, ENST00000695872, ENST00000695873, ENST00000695874, ENST00000695875, ENST00000695876, ENST00000695877, ENST00000899332, ENST00000970526

RefSeq mRNA: 2 — MANE Select: NM_006384 NM_001277764, NM_006384

CCDS: CCDS10360, CCDS73781

Canonical transcript exons

ENST00000328649 — 7 exons

Exon	Start	End
ENSE00001290832	90232219	90232327
ENSE00001291592	90231095	90231213
ENSE00001302723	90229975	90230505
ENSE00001309613	90230934	90231022
ENSE00001318820	90231357	90231507
ENSE00001329112	90233669	90233703
ENSE00003893836	90233835	90233941

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 99.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 62.1495 / max 480.2266, expressed in 1826 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151564	59.2626	1825
151565	1.3517	1008
151567	0.9844	419
151566	0.5441	297
151568	0.0068	3

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	99.42	gold quality
epithelium of bronchus	UBERON:0002031	99.36	gold quality
bronchus	UBERON:0002185	99.27	gold quality
mucosa of transverse colon	UBERON:0004991	99.16	gold quality
right uterine tube	UBERON:0001302	99.13	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.08	gold quality
body of pancreas	UBERON:0001150	98.94	gold quality
nasal cavity epithelium	UBERON:0005384	98.73	gold quality
granulocyte	CL:0000094	98.68	gold quality
right adrenal gland	UBERON:0001233	98.52	gold quality
left adrenal gland	UBERON:0001234	98.50	gold quality
left adrenal gland cortex	UBERON:0035825	98.49	gold quality
right adrenal gland cortex	UBERON:0035827	98.49	gold quality
right testis	UBERON:0004534	98.33	gold quality
left testis	UBERON:0004533	98.27	gold quality
adrenal cortex	UBERON:0001235	98.21	gold quality
transverse colon	UBERON:0001157	98.19	gold quality
small intestine Peyer’s patch	UBERON:0003454	98.19	gold quality
type B pancreatic cell	CL:0000169	98.15	gold quality
rectum	UBERON:0001052	98.14	gold quality
minor salivary gland	UBERON:0001830	98.09	gold quality
lower esophagus mucosa	UBERON:0035834	98.05	gold quality
right lobe of liver	UBERON:0001114	97.92	gold quality
pancreas	UBERON:0001264	97.88	gold quality
metanephros cortex	UBERON:0010533	97.88	gold quality
right lobe of thyroid gland	UBERON:0001119	97.83	gold quality
left lobe of thyroid gland	UBERON:0001120	97.81	gold quality
adenohypophysis	UBERON:0002196	97.81	gold quality
mucosa of paranasal sinus	UBERON:0005030	97.79	gold quality
nasal cavity mucosa	UBERON:0001826	97.70	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-MTAB-10283	yes	3556.23
E-GEOD-75688	yes	955.27
E-CURD-114	yes	60.85
E-HCAD-5	yes	34.95
E-HCAD-1	yes	28.01
E-MTAB-10287	yes	25.02
E-MTAB-8410	yes	16.52
E-GEOD-93593	yes	7.10
E-MTAB-6379	no	947.10
E-HCAD-4	no	19.93
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting CIB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-12132	99.47	68.90	1341
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-4520-3P	98.75	66.55	963
HSA-MIR-4701-5P	96.45	68.41	1121
HSA-MIR-588	96.45	68.36	1127
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-6775-3P	95.76	65.91	982

Literature-anchored findings (GeneRIF, showing 40)

• NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube. (PMID:11856312)
• describes regions within CIB and alpha(IIb) that interact with one another (PMID:12023286)
• An association between GPIIb/IIIa and calcium- and integrin-binding protein (CIB) is required for the process of platelet spreading. (PMID:12714504)
• CIB regulates platelet spreading through the regulation of FAK activation. (PMID:12881299)
• CIB may exist in multiple structural and metal ion-bound states in vivo which may play a role in its regulation of target proteins such as platelet integrin. (PMID:14992593)
• KIP has a role in telomere length maintenance and regulation (PMID:15190070)
• crystallographic structure of CIP1, an EF-hand-containing protein (PMID:15574431)
• calmyrin may be involved in the pathogenesis of AD. (PMID:15885068)
• Data indicate that although calmyrin forms stable covalent dimers in vitro, it most probably functions as a monomer in vivo. (PMID:15933764)
• CIB1 as a key regulator of PAK1 activation and signaling. (PMID:16061695)
• CIB1 appears to inhibit integrin activation by competing with talin for binding to alphaIIbbeta3, thus providing a model for tightly controlled regulation of alphaIIbbeta3 activation. (PMID:16418530)
• CIB1 is a ubiquitously expressed activating and inhibiting protein ligand of the InsP(3)R (PMID:16723353)
• Data report the structural characteristics of calcium- and integrin-binding protein 1 in solution and the mechanistic details of its interaction with a synthetic peptide derived from the alphaIIb integrin cytoplasmic domain. (PMID:16825200)
• communication between the paired EF-hand domains as well as between the N- and C-lobes of CIB1 is distinct from the ancestral proteins calmodulin and troponin C, which might be important for the unique function of CIB1 in numerous biological processes (PMID:17516631)
• The function of CIB1 on InsP3-evoked Ca2+ release from the ER is most likely mediated by its interaction with the InsP3 receptor. Thus, CIB1 seems to be an inhibitor of InsP3-dependent Ca2+ release in vivo. (PMID:18627437)
• Characterization of calcium- and integrin-binding protein 1 (CIB1) knockout platelets: potential compensation by CIB family members. (PMID:18989529)
• data identify low affinity (K(d), 10(-2)M) Ca(2+) binding events that influence the structures of the N- and C-terminal extensions of CIB1 under high (300 mM) Ca(2+) crystallization conditions (PMID:19388079)
• CIB1 interacts with SK1 in a Ca(2+)-dependent manner at the previously identified “calmodulin-binding site” of SK1. (PMID:19854831)
• content of DNA-PKcs was significantly higher in A549 cells than in H1299 cells (PMID:19923078)
• CIB1 may be a potential biomarker and target for therapeutic intervention of breast cancer. (PMID:20473878)
• Calcium- and integrin-binding protein 1 regulates microtubule organization and centrosome segregation through polo like kinase 3 during cell cycle progression. (PMID:20951827)
• CaMy1 via SCG10 couples Ca(2+) signals with the dynamics of microtubules during neuronal outgrowth in the developing brain. (PMID:21215777)
• analysis of Ca2+-CIB1 and Mg2+-CIB1 and their interactions with the platelet integrin alphaIIb cytoplasmic domain (PMID:21388953)
• results suggest that CIB1 positively regulates cell migration and is necessary for the recruitment of FAK to the focal adhesions. Furthermore, CIB1-induced cell migration is dependent on MAP kinase signaling and its function is attenuated by PAK1 (PMID:21748785)
• CIB1 may be used as a novel prognostic factor and possibly an attractive therapeutic target for hepatocellular carcinoma. (PMID:21857112)
• The CIB1 and calcineurin expression was increased in AF atrial tissue and was related to the type of AF. This finding suggests that CIB1 may be involved in the pathogenesis of AF in VHD patients. (PMID:22547769)
• Results indicate that CIB1 is uniquely positioned to regulate PI3K/AKT and MEK/ERK signaling and that simultaneous disruption of these pathways synergistically induces a nuclear GAPDH-dependent cell death. (PMID:22964641)
• CIB1a is a novel mediator of PKD2-driven carcinogenesis. (PMID:23503467)
• we present data that show that CIB1 binds to seven additional alpha-integrin CT peptides, bringing the total number of alpha-integrins that can associate with CIB1 to eight. (PMID:24011356)
• mRNA and protein expression levels of CIB1 were decreased in the oligoasthenozoospermia patients.CIB1 may be involved in the pathogenesis of oligoasthenozoospermia by the CDK1 signaling pathway. (PMID:24464679)
• these studies suggested that Kaposi’s sarcoma-associated herpesvirus utilizes CIB1 as one of the key molecule(s) to coordinate and sustain the EphA2 mediated signaling involved in its entry (PMID:24550731)
• High serum CIB1 levels are associated with pancreatic cancer.s (PMID:24585405)
• KIP binding to TRF2 enhances the telomere-binding activity of TRF2, suggesting that KIP acts as a positive regulator of TRF2 function. (PMID:25012820)
• a large subset of TNBCs depend on CIB1 for cell survival and tumor growth, independent of CIB1 expression levels. (PMID:26105795)
• this study identifies CIB1 and CIB2 as host helper factors for HIV-1 replication that are required for optimal receptor-mediated viral entry (PMID:27489023)
• we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca(2+)-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling. (PMID:27941888)
• Results suggest that interaction of CIB1 with alphaIIb is one of the early events occurring during outside-in signaling. Furthermore, CIB1 recruits FAK to the alphaIIbbeta3 complex at the filopodia where FAK is activated, which in turn activates c-Src, resulting in propagation of outside-in signaling leading to platelet spreading. (PMID:28542214)
• Study in human dopaminergic neuroblastoma SH-SY5Y cells revealed that CIB1 physically associates with ASK1, and thereby prevents ASK1 activation induced by 1-methyl-4-phenylpyrinidium (MPP+). CIB1 binds to the region containing amino acid residues 378-648 of ASK1. CIB1 depletion by RNA interference potentiates MPP+-induced dopaminergic neuronal death. (PMID:28939911)
• In summary, as a multifunctional protein, CIB1 serving not only as a Ca2+ modulating protein, most surprisingly, but also as an important potential tumor promoting factor. [review] (PMID:29017172)
• In patients with chronic stable ischemic heart failure, the diagnostic value of urine CIB1 outperforms that of serum pro-BNP (PMID:29028109)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	cib1	ENSDARG00000103118
mus_musculus	Cib1	ENSMUSG00000030538
rattus_norvegicus	Cib1	ENSRNOG00000033498
drosophila_melanogaster	CG32812	FBGN0025642
drosophila_melanogaster	Cib2	FBGN0034558
drosophila_melanogaster	elm	FBGN0037358
drosophila_melanogaster	CG14362	FBGN0038186
caenorhabditis_elegans	calm-1	WBGENE00009260
caenorhabditis_elegans		WBGENE00014109
caenorhabditis_elegans		WBGENE00019108

Paralogs (8): TESC (ENSG00000088992), CIB2 (ENSG00000136425), CIB3 (ENSG00000141977), CIB4 (ENSG00000157884), CHP2 (ENSG00000166869), CHP1 (ENSG00000187446), PPP3R2 (ENSG00000188386), PPP3R1 (ENSG00000221823)

Protein

Protein identifiers

Calcium and integrin-binding protein 1 — Q99828 (reviewed: Q99828)

Alternative names: Calcium- and integrin-binding protein, Calmyrin, DNA-PKcs-interacting protein, Kinase-interacting protein, SNK-interacting protein 2-28

All UniProt accessions (3): Q99828, A0A140VK09, A0A3B3ISY8

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-binding protein that plays a role in the regulation of numerous cellular processes, such as cell differentiation, cell division, cell proliferation, cell migration, thrombosis, angiogenesis, cardiac hypertrophy and apoptosis. Involved in bone marrow megakaryocyte differentiation by negatively regulating thrombopoietin-mediated signaling pathway. Participates in the endomitotic cell cycle of megakaryocyte, a form of mitosis in which both karyokinesis and cytokinesis are interrupted. Plays a role in integrin signaling by negatively regulating alpha-IIb/beta3 activation in thrombin-stimulated megakaryocytes preventing platelet aggregation. Up-regulates PTK2/FAK1 activity, and is also needed for the recruitment of PTK2/FAK1 to focal adhesions; it thus appears to play an important role in focal adhesion formation. Positively regulates cell migration on fibronectin in a CDC42-dependent manner, the effect being negatively regulated by PAK1. Functions as a negative regulator of stress activated MAP kinase (MAPK) signaling pathways. Down-regulates inositol 1,4,5-trisphosphate receptor-dependent calcium signaling. Involved in sphingosine kinase SPHK1 translocation to the plasma membrane in a N-myristoylation-dependent manner preventing TNF-induced apoptosis. Regulates serine/threonine-protein kinase PLK3 activity for proper completion of cell division progression. Plays a role in microtubule (MT) dynamics during neuronal development; disrupts the MT depolymerization activity of STMN2 attenuating NGF-induced neurite outgrowth and the MT reorganization at the edge of lamellipodia. Promotes cardiomyocyte hypertrophy via activation of the calcineurin/NFAT signaling pathway. Stimulates calcineurin PPP3R1 activity by mediating its anchoring to the sarcolemma. In ischemia-induced (pathological or adaptive) angiogenesis, stimulates endothelial cell proliferation, migration and microvessel formation by activating the PAK1 and ERK1/ERK2 signaling pathway. Also promotes cancer cell survival and proliferation. May regulate cell cycle and differentiation of spermatogenic germ cells, and/or differentiation of supporting Sertoli cells. Forms a complex with TMC6/EVER1 and TMC8/EVER2 in lymphocytes and keratynocytes where CIB1 stabilizes TMC6 and TMC8 levels and reciprocally. Acts as a restriction factor that promotes keratinocyte-intrinsic immunity to human beta-papillomaviruses (HPVs). Plays a regulatory role in angiogenesis and tumor growth by mediating PKD/PRKD2-induced vascular endothelial growth factor A (VEGFA) secretion.

Subunit / interactions. Monomer. Interacts with MYO1C. Interacts (via C-terminal region) with PPP3R1 and CACNA1C; the interactions increase upon cardiomyocytes hypertrophy. Interacts with the heterodimeric integrin alpha-IIb/beta3 (ITGA2B-ITGB3). Interacts with ITGA2B (via cytoplasmic domain); the interaction is direct and calcium-dependent. Interacts with the protein kinases PLK2/SNK and PRKDC (via the region immediately upstream of the kinase domain). Interacts with PLK3; the interaction inhibits PLK3 kinase activity. Interacts with PSEN2. Interacts (via C-terminus) with F8. Interacts with NBR1 (via C-terminus). Interacts with FEZ1 (via C-terminus). Interacts with UBR5 (via C-terminus); the interaction is sensitive to DNA damage, and may target CIB1 for ubiquitin-mediated degradation. Interacts with IFI6; the interaction is direct. Interacts with BCL2. Interacts with ITPR3; the interaction occurs in a calcium-dependent manner. Interacts with PTK2/FAK1. Interacts with MAP3K5; the interaction inhibits MAP3K5 activation by phosphorylation, and its subsequent interaction with TRAF2. Isoform 2 interacts with PRKD2 (via N-terminal AP-rich region), PTK2/FAK1 and PAK1. Interacts with TAS1R2 (via C-terminus); the interaction is independent of the myristoylation state of CIB1. Interacts (via C-terminal region) with STMN2 (via the N-terminal region); the interaction is direct, occurs in a calcium-dependent manner and attenuates the STMN2-induced neurite outgrowth inhibition. Interacts with SPHK1, the interaction occurs in a calcium-dependent manner. Interacts with ITGA2B (via C-terminal cytoplasmic tail); the interaction occurs upon platelet aggregation and is stabilized/increased in a calcium and magnesium-dependent manner. Interacts with PAK1 (via N-terminal region); the interaction is direct and occurs in a calcium-dependent manner. Interacts with RAC3 (via C-terminal region); the interaction induces their association with the cytoskeleton upon alpha-IIb/beta3 integrin-mediated adhesion. Interacts with ITGA5 and ITGAV. Interacts and forms a complex with TMC6 and TMC8; the interaction stabilizes each component of the complex. (Microbial infection) Interacts with human papillomavirus 4/HPV4 protein E8, human papillomavirus 5/HPV5 protein E1, and human papillomavirus 16/HPV16 proteins E2 and E5.

Subcellular location. Membrane. Cell membrane. Sarcolemma. Apical cell membrane. Cell projection. Ruffle membrane. Filopodium tip. Growth cone. Lamellipodium. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Perinuclear region. Nucleus. Neuron projection. Perikaryon Cytoplasm. Golgi apparatus. trans-Golgi network.

Tissue specificity. Ubiquitously expressed. Expressed in the epidermis, hair follicles and keratinocytes. Detected in platelets and in cell lines of megakaryocytic and erythrocytic lineages. Both isoform 1 and isoform 2 are detected in various cancer cell lines, with isoform 2 being the predominant form (at protein level).

Post-translational modifications. Phosphorylation of isoform 2 at Ser-118 by PRKD2 increases its ability to stimulate tumor angiogenesis.

Disease relevance. Epidermodysplasia verruciformis 3 (EV3) [MIM:618267] A form of epidermodysplasia verruciformis, a rare genodermatosis associated with a high risk of skin carcinoma that results from an abnormal susceptibility to infection by specific human papillomaviruses, including the oncogenic HPV5. Infection leads to the early development of disseminated flat wart-like and pityriasis versicolor-like skin lesions. Cutaneous Bowen’s carcinomas in situ and invasive squamous cell carcinomas develop in about half of the patients, mainly on sun-exposed skin areas. EV3 inheritance is autosomal recessive. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The EF-hands may also bind magnesium ions in the presence of high Mg(2+) levels and low Ca(2+) levels.

Induction. Up-regulated during breast cancer progression.

Miscellaneous. The binding of either calcium or magnesium significantly increases the structural stability of the protein in comparison to apo-CIB (calcium- and magnesium-free form).

Isoforms (2)

UniProt ID	Names	Canonical?
Q99828-1	1	yes
Q99828-2	2, CIB1a

RefSeq proteins (2): NP_001264693, NP_006375* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR051433	CIBP	Family

Pfam: PF13499

UniProt features (54 total): mutagenesis site 13, helix 13, binding site 10, strand 4, sequence variant 3, domain 2, sequence conflict 2, turn 2, initiator methionine 1, chain 1, lipid moiety-binding region 1, splice variant 1, modified residue 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
6OCX	X-RAY DIFFRACTION	1.9
1XO5	X-RAY DIFFRACTION	1.99
6OD0	X-RAY DIFFRACTION	2.15
1Y1A	X-RAY DIFFRACTION	2.3
1DGU	SOLUTION NMR
1DGV	SOLUTION NMR
2L4H	SOLUTION NMR
2L4I	SOLUTION NMR
2LM5	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99828-F1	76.37	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (10): 163; 165; 167; 172; 116; 118; 120; 122; 127; 161

Post-translational modifications (2): 2, 118

Mutagenesis-validated functional residues (13):

Position	Phenotype
2	inhibits translocation to the plasma membrane. increased apoptosis after tnf stimulation.
78	loss of phosphorylation by pkd/prkd2; in isoform 2.
78	phosphomimetic; promotes tumor growth by an indirect mechanism; in isoform 2.
114–117	loss of binding to itgav.
115	loss of binding to itga2b.
127	cytoplasmic localization.
131	loss of binding to itga2b.
152–153	loss of binding to itga2b.
153	loss of binding to itga2b.
167	no effect on phosphorylation by pkd/prkd2; in isoform 2.
172	cytoplasmic localization.
173	loss of binding to itga2b.
173	loss of binding to itga2b. does not inhibit interaction with pak1.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 425 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_POSITIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_RESPONSE_TO_PEPTIDE, MODULE_151, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_CELL_MIGRATION_INVOLVED_IN_SPROUTING_ANGIOGENESIS, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_PROTEIN_TARGETING, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE

GO Biological Process (43): angiogenesis (GO:0001525), negative regulation of protein phosphorylation (GO:0001933), positive regulation of protein phosphorylation (GO:0001934), positive regulation of cell-matrix adhesion (GO:0001954), response to ischemia (GO:0002931), double-strand break repair (GO:0006302), apoptotic process (GO:0006915), DNA damage response (GO:0006974), negative regulation of microtubule depolymerization (GO:0007026), endomitotic cell cycle (GO:0007113), cell adhesion (GO:0007155), spermatid development (GO:0007286), positive regulation of cell population proliferation (GO:0008284), negative regulation of cell population proliferation (GO:0008285), negative regulation of neuron projection development (GO:0010977), platelet formation (GO:0030220), positive regulation of cell growth (GO:0030307), positive regulation of cell migration (GO:0030335), cytoplasmic microtubule organization (GO:0031122), positive regulation of cell adhesion mediated by integrin (GO:0033630), thrombopoietin-mediated signaling pathway (GO:0038163), regulation of cell population proliferation (GO:0042127), negative regulation of apoptotic process (GO:0043066), positive regulation of catalytic activity (GO:0043085), negative regulation of megakaryocyte differentiation (GO:0045653), obsolete positive regulation of NF-kappaB transcription factor activity (GO:0051092), cell division (GO:0051301), regulation of cell division (GO:0051302), negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051898), positive regulation of ERK1 and ERK2 cascade (GO:0070374), positive regulation of calcineurin-NFAT signaling cascade (GO:0070886), cellular response to tumor necrosis factor (GO:0071356), cellular response to growth factor stimulus (GO:0071363), positive regulation of protein serine/threonine kinase activity (GO:0071902), positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050), positive regulation of protein targeting to membrane (GO:0090314), extrinsic apoptotic signaling pathway (GO:0097191), positive regulation of substrate adhesion-dependent cell spreading (GO:1900026), positive regulation of protein localization to plasma membrane (GO:1903078), cellular response to nerve growth factor stimulus (GO:1990090)

GO Molecular Function (9): magnesium ion binding (GO:0000287), calcium ion binding (GO:0005509), calcium-dependent protein kinase inhibitor activity (GO:0008427), protein serine/threonine kinase inhibitor activity (GO:0030291), small GTPase binding (GO:0031267), protein-membrane adaptor activity (GO:0043495), transmembrane transporter binding (GO:0044325), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (25): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), centrosome (GO:0005813), plasma membrane (GO:0005886), membrane (GO:0016020), apical plasma membrane (GO:0016324), nuclear body (GO:0016604), lamellipodium (GO:0030027), axon (GO:0030424), growth cone (GO:0030426), vesicle (GO:0031982), filopodium tip (GO:0032433), ruffle membrane (GO:0032587), sarcolemma (GO:0042383), neuron projection (GO:0043005), neuronal cell body (GO:0043025), perikaryon (GO:0043204), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), cell periphery (GO:0071944), cytoskeleton (GO:0005856), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
intracellular membrane-bounded organelle	3
anatomical structure formation involved in morphogenesis	2
regulation of protein phosphorylation	2
protein phosphorylation	2
cell population proliferation	2
regulation of cell population proliferation	2
positive regulation of cellular process	2
metal ion binding	2
cytoplasm	2
endomembrane system	2
plasma membrane bounded cell projection	2
blood vessel morphogenesis	1
negative regulation of protein modification process	1
negative regulation of phosphorylation	1
positive regulation of protein modification process	1
positive regulation of phosphorylation	1
regulation of cell-matrix adhesion	1
cell-matrix adhesion	1
positive regulation of cell-substrate adhesion	1
response to stress	1
DNA repair	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to stress	1
microtubule depolymerization	1
negative regulation of microtubule polymerization or depolymerization	1
regulation of microtubule depolymerization	1
negative regulation of protein depolymerization	1
negative regulation of supramolecular fiber organization	1
mitotic cell cycle	1
cellular process	1
germ cell development	1
spermatid differentiation	1
negative regulation of cellular process	1
regulation of neuron projection development	1
neuron projection development	1
negative regulation of cell projection organization	1
myeloid cell differentiation	1

Protein interactions and networks

STRING

2365 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CIB1	CRY2	Q49AN0	996
CIB1	ITGA2B	P08514	968
CIB1	PSEN2	P49810	941
CIB1	ATG13	O75143	939
CIB1	ATG101	Q9BSB4	922
CIB1	CDK2	P24941	848
CIB1	CDK4	P11802	837
CIB1	GUF1	Q8N442	816
CIB1	CCNL2	Q96S94	806
CIB1	CDKN1C	P49918	781
CIB1	TMC8	Q8IU68	696
CIB1	CCND1	P24385	667
CIB1	PLK3	Q9H4B4	664
CIB1	PRKDC	P78527	656
CIB1	ULK2	Q8IYT8	653
CIB1	ARHGEF7	Q14155	653

IntAct

154 interactions, top by confidence:

A	B	Type	Score
MAP3K5	TXN	psi-mi:“MI:0914”(association)	0.680
CIB1	MAP3K5	psi-mi:“MI:0407”(direct interaction)	0.660
CIB1	MAP3K5	psi-mi:“MI:0915”(physical association)	0.660
MAP3K5	CIB1	psi-mi:“MI:0915”(physical association)	0.660
CIB1	STMN2	psi-mi:“MI:0403”(colocalization)	0.660
CIB1	STMN2	psi-mi:“MI:0915”(physical association)	0.660
CIB1	STMN2	psi-mi:“MI:0407”(direct interaction)	0.660
STMN2	CIB1	psi-mi:“MI:0915”(physical association)	0.660
STMN2	CIB1	psi-mi:“MI:2364”(proximity)	0.660
CIB1	STMN2	psi-mi:“MI:2364”(proximity)	0.660
WASL	CIB1	psi-mi:“MI:0915”(physical association)	0.630
CIB1	WASL	psi-mi:“MI:0915”(physical association)	0.630
CIB1	WASL	psi-mi:“MI:0407”(direct interaction)	0.630
NCK2	CIB1	psi-mi:“MI:0915”(physical association)	0.560
EIF4G1	CIB1	psi-mi:“MI:0915”(physical association)	0.560
CD27	CIB1	psi-mi:“MI:0915”(physical association)	0.560
TMEM95	CIB1	psi-mi:“MI:0915”(physical association)	0.560
GLIS3	CIB1	psi-mi:“MI:0915”(physical association)	0.560
NME4	CIB1	psi-mi:“MI:0915”(physical association)	0.560
ONECUT3	CIB1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (123): CIB1 (Two-hybrid), CIB1 (Affinity Capture-Western), CIB1 (Two-hybrid), CIB1 (Reconstituted Complex), CIB1 (Two-hybrid), CIB1 (Affinity Capture-MS), CIB1 (Affinity Capture-MS), CIB1 (Affinity Capture-Western), CIB1 (Affinity Capture-Western), CIB1 (Affinity Capture-Western), ITGA2B (Affinity Capture-Western), ITGA5 (Affinity Capture-Western), ITGB3 (Affinity Capture-Western), MAP3K5 (Reconstituted Complex), CIB1 (Two-hybrid)

ESM2 similar proteins: A0PJX0, A1L1L6, A4IG32, B1A8Z2, B1H2N3, C7A278, D2HZB0, O88456, P04632, P06813, P07090, P22676, P47728, Q08331, Q0IIL1, Q17QE5, Q1RMX9, Q2HJF8, Q2KI69, Q32L26, Q32LU1, Q3T0E8, Q3ZBY3, Q4R518, Q5PPL2, Q5RDF9, Q5ZM73, Q6NVC5, Q6P6Q9, Q6P8Y1, Q6PHZ8, Q6PIL6, Q8BG51, Q8HYN7, Q8IXI2, Q8R426, Q8VCX5, Q8WWF8, Q99828, Q99MG9

Diamond homologs: A0PJX0, B1A8Z2, C7A276, C7A278, O75838, Q0IQB6, Q0IUU4, Q0P523, Q17QE5, Q3KQ77, Q568Z7, Q6PC72, Q96Q77, Q99828, Q9D9N5, Q9R010, Q9W2Q5, Q9Y6T7, Q9Z0F4, Q9Z309, G5EDN6, P28470, P63098, P63099, P63100, Q2TBI5, Q3HRN8, Q3HRN9, Q63810, Q63811, Q6CGE6, Q7XC27, Q96LZ3, Q9LTB8, O81223, O81445, P06707, P06708, P0CM54, P0CM55

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CIB1	“down-regulates activity”	“AIIB/b3 integrin”	binding
STUB1	“down-regulates quantity”	CIB1	ubiquitination
RAC3	“up-regulates activity”	CIB1	binding
CIB1	“up-regulates activity”	ITGA2B	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

289 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	10
Likely pathogenic	5
Uncertain significance	145
Likely benign	91
Benign	15

Top pathogenic / likely-pathogenic (15)

Variant ID	HGVS	Classification
1458030	NM_006384.4(CIB1):c.350_351del (p.Asp116_Phe117insTer)	Pathogenic
1918754	NM_006384.4(CIB1):c.87-111C>G	Pathogenic
2698752	NM_006384.4(CIB1):c.242dup (p.Ala82fs)	Pathogenic
3015395	NM_006384.4(CIB1):c.8del (p.Gly3fs)	Pathogenic
3692093	NM_006384.4(CIB1):c.132del (p.Ser44fs)	Pathogenic
3693158	NM_006384.4(CIB1):c.413_414del (p.Glu138fs)	Pathogenic
4716429	NM_006384.4(CIB1):c.87-29_87-20del	Pathogenic
4731614	NM_006384.4(CIB1):c.235_239del (p.Thr79fs)	Pathogenic
599257	NM_006384.4(CIB1):c.214C>T (p.Arg72Ter)	Pathogenic
599258	NM_006384.4(CIB1):c.52-2A>G	Pathogenic
3065461	NM_006384.4(CIB1):c.465+1G>A	Likely pathogenic
3256944	NM_006384.4(CIB1):c.461del (p.Asp154fs)	Likely pathogenic
3256950	NM_006384.4(CIB1):c.465+1del	Likely pathogenic
3685319	NM_006384.4(CIB1):c.87-121G>T	Likely pathogenic
3779081	NM_006384.4(CIB1):c.7_8del (p.Gly3fs)	Likely pathogenic

SpliceAI

1114 predictions. Top by Δscore:

Variant	Effect	Δscore
15:90230928:TCATA:T	donor_loss	1.0000
15:90230929:CATA:C	donor_loss	1.0000
15:90230930:ATACC:A	donor_loss	1.0000
15:90230931:TACC:T	donor_loss	1.0000
15:90230932:A:AT	donor_loss	1.0000
15:90230933:C:CT	donor_loss	1.0000
15:90231086:G:C	donor_gain	1.0000
15:90231093:A:AC	donor_gain	1.0000
15:90231094:C:CC	donor_gain	1.0000
15:90231094:CG:C	donor_gain	1.0000
15:90231209:AAAGT:A	acceptor_gain	1.0000
15:90231210:AAGT:A	acceptor_gain	1.0000
15:90231211:AGT:A	acceptor_gain	1.0000
15:90231212:GT:G	acceptor_gain	1.0000
15:90231214:C:A	acceptor_loss	1.0000
15:90231214:C:CC	acceptor_gain	1.0000
15:90231215:T:G	acceptor_loss	1.0000
15:90231222:C:CT	acceptor_gain	1.0000
15:90231223:A:T	acceptor_gain	1.0000
15:90231226:C:CT	acceptor_gain	1.0000
15:90231228:C:CT	acceptor_gain	1.0000
15:90231229:A:T	acceptor_gain	1.0000
15:90231352:CT:C	donor_loss	1.0000
15:90231353:TCAC:T	donor_loss	1.0000
15:90231354:CACCA:C	donor_loss	1.0000
15:90231355:A:AC	donor_gain	1.0000
15:90231355:A:C	donor_loss	1.0000
15:90231356:C:CC	donor_gain	1.0000
15:90232214:TGCAC:T	donor_loss	1.0000
15:90232215:GCACC:G	donor_loss	1.0000

AlphaMissense

1266 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:90230969:G:C	F173L	0.999
15:90230969:G:T	F173L	0.999
15:90230970:A:G	F173S	0.999
15:90230971:A:G	F173L	0.999
15:90231105:A:G	L152P	0.999
15:90231367:G:C	F112L	0.999
15:90231367:G:T	F112L	0.999
15:90231369:A:G	F112L	0.999
15:90231382:C:A	K107N	0.999
15:90231382:C:G	K107N	0.999
15:90230973:T:A	E172V	0.998
15:90231177:A:G	L128P	0.998
15:90231192:A:G	L123S	0.998
15:90231368:A:G	F112S	0.998
15:90231371:G:T	A111D	0.998
15:90231415:A:C	S96R	0.998
15:90231415:A:T	S96R	0.998
15:90231417:T:G	S96R	0.998
15:90231428:A:G	L92P	0.998
15:90231369:A:T	F112I	0.997
15:90231398:G:T	A102D	0.997
15:90231422:A:G	L94P	0.997
15:90231472:G:C	F77L	0.997
15:90231472:G:T	F77L	0.997
15:90231474:A:G	F77L	0.997
15:90232223:A:G	L64P	0.997
15:90233690:A:G	L22P	0.997
15:90230499:A:C	F187L	0.996
15:90230499:A:T	F187L	0.996
15:90230501:A:G	F187L	0.996

dbSNP variants (sampled 300 via entrez): RS1000076565 (15:90233564 C>G), RS1000076592 (15:90257050 A>G,T), RS1000127743 (15:90261675 G>A,T), RS1000258463 (15:90250306 G>A), RS1000472786 (15:90234979 A>G), RS1000515748 (15:90249955 A>T), RS1000551771 (15:90250252 C>T), RS1000723477 (15:90261924 C>A,T), RS1000868902 (15:90234174 G>A,C,T), RS1000884319 (15:90237821 A>C), RS1000915361 (15:90238042 G>A,C), RS1000982471 (15:90251669 G>A), RS1001092063 (15:90243918 G>T), RS1001280062 (15:90256572 T>C), RS1001354110 (15:90230049 C>G)

Disease associations

OMIM: gene MIM:602293 | disease phenotypes: MIM:618267

GenCC curated gene-disease

Disease	Classification	Inheritance
epidermodysplasia verruciformis, susceptibility to, 3	Definitive	Autosomal recessive
epidermodysplasia verruciformis	Supportive	Autosomal recessive

Mondo (3): breast ductal adenocarcinoma (MONDO:0005590), epidermodysplasia verruciformis, susceptibility to, 3 (MONDO:0032644), epidermodysplasia verruciformis (MONDO:0009176)

Orphanet (0):

HPO phenotypes

18 total (18 of 18 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0001051	Seborrheic dermatitis
HP:0001053	Hypopigmented skin patches
HP:0001581	Recurrent skin infections
HP:0002671	Basal cell carcinoma
HP:0002715	Abnormality of the immune system
HP:0002860	Squamous cell carcinoma
HP:0003621	Juvenile onset
HP:0007565	Multiple cafe-au-lait spots
HP:0010610	Palmar pits
HP:0011462	Young adult onset
HP:0011463	Childhood onset
HP:0025092	Epidermal acanthosis
HP:0100585	Telangiectasia of the skin
HP:0200034	Papule
HP:0200035	Skin plaque
HP:0200039	Pustule
HP:0200043	Verrucae

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D004819	Epidermodysplasia Verruciformis	C01.925.256.650.810.345; C01.925.825.810.260; C01.925.928.914.345; C17.800.838.790.810.260

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4879503 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

33 potent at pChembl≥5 of 34 total, top 33 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.22	Kd	6	nM	CHEMBL4879386
8.05	IC50	9	nM	CHEMBL4872793
8.05	IC50	9	nM	CHEMBL5027915
7.92	IC50	12	nM	CHEMBL4879386
7.92	IC50	12	nM	CHEMBL4847488
7.82	IC50	15	nM	CHEMBL4875466
7.82	IC50	15	nM	CHEMBL4851034
7.53	Kd	29.4	nM	CHEMBL4872329
7.40	IC50	40	nM	CHEMBL4851160
7.29	IC50	51	nM	CHEMBL4846980
7.27	IC50	54	nM	CHEMBL4874071
7.23	IC50	59	nM	CHEMBL4854255
7.23	IC50	59	nM	CHEMBL4869011
7.19	IC50	65	nM	CHEMBL4851775
7.17	IC50	67	nM	CHEMBL4871134
7.14	IC50	72	nM	CHEMBL4865306
7.12	IC50	76	nM	CHEMBL4852205
6.77	IC50	170	nM	CHEMBL4864176
6.72	IC50	190	nM	CHEMBL4872183
6.72	IC50	190	nM	CHEMBL4861668
6.64	IC50	230	nM	CHEMBL4860806
6.52	IC50	300	nM	CHEMBL4855095
6.37	IC50	430	nM	CHEMBL4869651
6.33	IC50	470	nM	CHEMBL4849368
6.09	IC50	820	nM	CHEMBL4860058
6.08	IC50	840	nM	CHEMBL4853292
5.82	IC50	1500	nM	CHEMBL4851142
5.75	IC50	1800	nM	CHEMBL4860554
5.75	IC50	1800	nM	CHEMBL4867763
5.60	IC50	2500	nM	CHEMBL4850156
5.41	IC50	3900	nM	CHEMBL4877672
5.38	IC50	4200	nM	CHEMBL4858504
5.15	IC50	7100	nM	CHEMBL4855813

PubChem BioAssay actives

33 with measured affinity, of 49 total; 32 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766554: Binding affinity to full length CIB1 (unknown origin) at 300 uM by isothermal titration calorimetry	kd	0.0060	uM
(3R,6S,9S,12S,15S,18S,21S,24S,27S,30S,33S)-30-(4-aminobutyl)-9-(2-amino-2-oxoethyl)-27-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-21,33-bis[(4-hydroxyphenyl)methyl]-6,18-bis(1H-indol-3-ylmethyl)-24-methyl-15-(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35-undecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34-undecazacyclohexatriacontane-3-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0090	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0090	uM
(6S,9S,15S,18S,21S,24S,27S,30S,33S)-24-[(2S)-butan-2-yl]-21-[3-(diaminomethylideneamino)propyl]-6,27-bis[(1R)-1-hydroxyethyl]-9-[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-2,5,8,11,17,20,23,26,29,32-decaoxo-13-thia-1,4,7,10,16,19,22,25,28,31-decazabicyclo[31.3.0]hexatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0120	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-27-methyl-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0150	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-27-(2-amino-2-oxoethyl)-18-benzyl-24,33-bis[(2S)-butan-2-yl]-21-[3-(diaminomethylideneamino)propyl]-3,6-bis[(1R)-1-hydroxyethyl]-9-[(4-hydroxyphenyl)methyl]-30-(1H-indol-3-ylmethyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0150	uM
(4S)-5-[[(2S)-1-[[2-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-[[4-[2-[2-(6-chlorohexoxy)ethoxy]ethylamino]-4-oxobutanoyl]amino]-5-oxopentanoic acid	1766554: Binding affinity to full length CIB1 (unknown origin) at 300 uM by isothermal titration calorimetry	kd	0.0294	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-3-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0400	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-4,6-dimethyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0510	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6,7,31-trimethyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0540	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-31-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0590	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-6-butyl-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-21,27-bis(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0590	uM
(3R,6S,9S,12S,15S,18S,21S,24S,27S,30S,33S)-9-(2-amino-2-oxoethyl)-27,30-bis(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-(3-carbamimidamidopropyl)-21-[(1R)-1-hydroxyethyl]-24-(hydroxymethyl)-33-[(4-hydroxyphenyl)methyl]-6,18-bis(1H-indol-3-ylmethyl)-5,8,11,14,17,20,23,26,29,32,35-undecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34-undecazacyclohexatriacontane-3-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0650	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6,34-dimethyl-21,27-bis(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0670	uM
(3R,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-6-butyl-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-10,19,31-trimethyl-3,27-bis(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0720	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-21-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.0760	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-24-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.1700	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-21-(furan-2-ylmethyl)-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6,7,31-trimethyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.1900	uM
(6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6,7,31-trimethyl-3-(3-methylbutyl)-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.1900	uM
(3S,6S,9S,15R,18S,21S,26S,29S,32S,35S,38S)-21-amino-6-(4-aminobutyl)-3-(3-amino-3-oxopropyl)-18,32-bis(1-benzothiophen-3-ylmethyl)-26-[(2S)-butan-2-yl]-9,35-bis[(4-hydroxyphenyl)methyl]-29-(2-methylpropyl)-2,5,8,11,17,20,23,25,28,31,34,37-dodecaoxo-13-thia-1,4,7,10,16,19,24,27,30,33,36-undecazabicyclo[36.3.0]hentetracontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.2300	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-33-benzyl-24-[(2S)-butan-2-yl]-9-[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-3,6-dimethyl-21,27-bis(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.3000	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18-(1H-indol-3-ylmethyl)-30-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.4300	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9-[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-33-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.4700	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-3,6,21-trimethyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.8200	uM
(3R,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-6-butyl-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-10-methyl-3-(3-methylbutyl)-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	0.8400	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-24-[(2S)-butan-2-yl]-6-butyl-21-(furan-2-ylmethyl)-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-3-(3-methylbutyl)-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	1.5000	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S)-6-(4-aminobutyl)-3-(3-amino-3-oxopropyl)-21-[(2S)-butan-2-yl]-9,30-bis[(4-hydroxyphenyl)methyl]-18,27-bis(1H-indol-3-ylmethyl)-19-methyl-24-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32-decaoxo-13-thia-1,4,7,10,16,19,22,25,28,31-decazabicyclo[31.3.0]hexatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	1.8000	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-21-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6,10,34-trimethyl-3-(3-methylbutyl)-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	1.8000	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-33-[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-9-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	2.5000	uM
(3S,6S,9S,15R,18S,21R,24S,27S,30S,33S,36S)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-6-butyl-21-(furan-2-ylmethyl)-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-10,34-dimethyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	3.9000	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-24-[(2S)-butan-2-yl]-21-(furan-2-ylmethyl)-9,33-bis[(4-hydroxyphenyl)methyl]-18,30-bis(1H-indol-3-ylmethyl)-6,7-dimethyl-3-(3-methylbutyl)-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	4.2000	uM
(3S,6S,9S,15R,18S,21S,24S,27S,30S,33S,36S)-6-(4-aminobutyl)-21-(2-amino-2-oxoethyl)-3-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-9,33-bis[(4-hydroxyphenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-methyl-27-(2-methylpropyl)-2,5,8,11,17,20,23,26,29,32,35-undecaoxo-13-thia-1,4,7,10,16,19,22,25,28,31,34-undecazabicyclo[34.3.0]nonatriacontane-15-carboxamide	1766553: Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	ic50	7.1000	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, increases methylation	8
Smoke	decreases expression, increases abundance, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
pradimicin-IRD	increases expression, affects expression, affects response to substance	1
triphenyl phosphate	affects expression	1
VX-agent	increases expression	1
perfluorooctanoic acid	increases expression	1
doxifluridine	increases response to substance	1
perfluorooctane sulfonic acid	increases expression	1
S 1 (combination)	increases response to substance	1
azoxystrobin	increases expression	1
chloropicrin	increases expression	1
2-palmitoylglycerol	increases expression	1
CPG-oligonucleotide	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
pyrachlostrobin	increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
picoxystrobin	increases expression	1
Capecitabine	increases response to substance	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	increases methylation	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	increases expression	1
Diethylhexyl Phthalate	increases expression	1
Doxorubicin	increases expression	1
Hydralazine	increases expression, affects cotreatment	1

ChEMBL screening assays

12 unique, capped per target: 12 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4825642	Binding	Displacement of Alexa Fluor 647 labelled UNC10245092 peptide from CIB1 (unknown origin) preincubated for 20 mins followed by Alexa-CIB1 phage peptide addition and measured after 20 to 30 mins by TR-FRET assay	Discovery and Development of Cyclic Peptide Inhibitors of CIB1. — ACS Med Chem Lett

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2UC	Abcam HEK293T CIB1 KO	Transformed cell line	Female
CVCL_D6SH	WAe009-A-1Z	Embryonic stem cell	Female

Clinical trials (associated diseases)

12 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00973856	Not specified	COMPLETED	Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery